Evidence map›Paper›PMID 42577802›Full record

Trial reportOpen forum infectious diseases2026

Cefadroxil as Oral Transitional Therapy for Gram-Positive Bacteremia With or Without Non-Vertebral Osteomyelitis: A Multicenter Retrospective Cohort Study.

Devin C Clark, Rachel Baden, Josh Banerjee, Rita Bedrossian, Hannah Chute, Kusha Davar, Derek Deng, Matthew Donnelly, Daisy Fernandez, Reid Goodman and 17 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Devin C ClarkDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0001-4927-4657
Rachel BadenDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0004-5620-7286
Josh BanerjeeDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-3918-0120
Rita BedrossianDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0002-6568-4063
Hannah ChuteDepartment of Medicine, Keck School of Medicine of USC, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-3815-6081
Kusha DavarDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-5153-2264
Derek DengDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0008-0404-8489
Matthew DonnellyDepartment of Pharmacy, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, California, USA.ORCID https://orcid.org/0009-0007-3434-6877
Daisy FernandezDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Reid GoodmanDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7118-6100
Hugh GordonDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7856-6173
Emerson HarrisDepartment of Medicine, Keck School of Medicine of USC, Los Angeles, California, USA.
Douglass HutcheonDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Arthur JengDepartment of Medicine, Division of Infectious Diseases, Olive View-UCLA Medical Center, Sylmar, California, USA.
Vaishnavi KolluruDepartment of Medicine, University of Southern California, Los Angeles, California, USA.
Pamela LeeDepartment of Medicine, Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA.ORCID https://orcid.org/0000-0001-9058-529X
Esteban MartinezDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Loren G MillerDepartment of Medicine, Division of Infectious Diseases, Harbor-UCLA Medical Center, Torrance, California, USA.
Emi MinejimaDepartment of Pharmacy, University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences, Los Angeles, California, USA.
Vadym MykhaylovDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Madelyn PerezDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Dana RussellDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Varsha SrinivasaDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Ishaque SyedDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.
Noah Wald-DicklerDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-8782-5395
Brad SpellbergDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-3632-1709
Sarah R FrelingDepartment of Medicine, Los Angeles General Medical Center, Los Angeles, California, USA.ORCID https://orcid.org/0009-0007-2414-2766

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oral cefadroxil has favorable pharmacokinetics for the treatment of bloodstream infection (BSI) and osteomyelitis caused by Gram-positive cocci (GPC), but limited clinical data exist. Methods: We conducted a multicenter, retrospective cohort study between September 2022 and April 2025 assessing cefadroxil versus intravenous (IV)-only or other oral transitional therapy in adults with susceptible GPC BSI, with or without osteomyelitis. No patients with endocarditis, vertebral osteomyelitis, or prosthetic or central nervous system infections were included. Primary outcome was treatment success, defined as 90-day survival without infection progression or relapse. Prioritized secondary outcomes included all-cause mortality, recurrent bacteremia, and readmission at 90 days. Results: Of 323 patients with BSI, 58 were treated with cefadroxil, 72 IV only, and 193 with other oral antibiotics. Rates of osteomyelitis were comparable in each cohort, but skin and soft-tissue infections were a more common source of bacteremia in cefadroxil (52%) than either IV (28%, Conclusions: We found similar outcomes for cefadroxil and IV or PO alternatives in patients with GPC BSI, absent endocarditis, vertebral osteomyelitis, prosthetic or central nervous system infection. Cefadroxil was well-tolerated without observed severe adverse events. Main Point: In this multicenter, retrospective cohort study, cefadroxil was an effective and safe oral transitional therapy for bloodstream infections, with or without nonvertebral osteomyelitis.

Indexed as

bacteremiacefadroxilosteomyelitisstewardship

Identifiers

PMID42577802
PMCPMC13455355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.